Bionomics (NASDAQ:BNOX) Downgraded by HC Wainwright to Neutral
Bionomics (NASDAQ:BNOX) Downgraded by HC Wainwright to Neutral
HC Wainwright downgraded shares of Bionomics (NASDAQ:BNOX – Get Rating) from a buy rating to a neutral rating in a report issued on Monday, The Fly reports.
溫賴特 HC 降級的股票 生物學 (納斯達克:BNOX — 獲得評分) 從購買評級到星期一發布的報告中的中立評級,《飛行》報告。
Separately, Loop Capital initiated coverage on shares of Bionomics in a research report on Tuesday, November 1st. They issued a buy rating and a $23.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $16.67.
另外,環資本在 11 月 1 日(星期二)的一份研究報告中開始對生物學股份的覆蓋。他們為該公司發出了買入評級和 23.00 美元的目標價格。兩位股票研究分析師對該股票進行了持有評級,其中四名股票給予買入評級。根據 MarketBeat 的數據,該股票目前的平均評級為中等買入,共識目標價為 16.67 美元。
Bionomics Price Performance
生物學價格性能
NASDAQ BNOX opened at $4.71 on Monday. The company has a fifty day simple moving average of $7.51 and a 200 day simple moving average of $7.33. Bionomics has a 12-month low of $4.71 and a 12-month high of $13.76.
納斯達克 BNOX 週一開盤價為 4.71 美元。該公司有五十天的簡單移動平均線 7.51 美元和 200 天的簡單移動平均線 7.33 美元。生物學具有 12 個月低點 4.71 美元,12 個月高點為 13.76 美元。
Bionomics Company Profile
生物學公司簡介
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Biomics Limited 是一家臨床階段生物製藥公司,發現並開發用於治療中樞神經系統疾病和癌症的新型候選藥物。公司的主要候選藥物包括 BNC210,一種 a7 菸鹼乙酰膽鹼受體的陰性同種異體調節劑,該藥物正處於治療社交焦慮症的 2 期臨床試驗中,以及用於治療創傷後應激障礙的 2b 期臨床試驗。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Bionomics (BNOX)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- 獲取有關生物學(BNOX)的研究報告的免費副本
- 您購買 Palantir 的決定可能只是時間問題
- 卡特彼勒和迪爾是否在 2023 年設置集會?
- 馬倫汽車獲取一個顛簸作為 I-GO 到達歐洲
- 在 2023 年,陽光會在這 3 個大型股太陽能股上閃耀嗎?
- 清醒汽車面臨的現實可能會影響看漲的感知
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收生物學的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收生物學和相關公司的最新新聞和分析師評級的簡要每日摘要。